Phelan-McDermid Syndrome and the JAG201 Study
Alex Kolevzon, MD, Clinical Director of the Seaver Autism Center at Mount Sinai, discusses Phelan-McDermid syndrome and the JAG201 study.
Alex Kolevzon, MD, Clinical Director of the Seaver Autism Center at Mount Sinai, discusses Phelan-McDermid syndrome and the JAG201 study.
Roughly 11% of active pharmaceutical ingredients produced for the US market were linked to generic drug shortages in 2020 and 2021.
Findings from the phase 3 DESTINY-Breast06 trial will be presented at a future medical meeting and shared with regulatory authorities.
Along with his wife, Lorna, one individual has been there for Robert Jenkins nearly every step of the way: his oncologist Eric Jacobsen, MD.
Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.
OncLive® State of the Science Summit: Disease State, Month Day, Year. Oncology live event features research and clinical advances in oncology.
Trastuzumab deruxtecan enhanced survival without disease progression compared with chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.
With the high out-of-pocket costs for cancer care, nearly 60% of working-age cancer survivors report experiencing at least one type of financial hardship, including being…
Programmed cell death protein 1(PD-1) axis blockade has become the mainstay in the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer…
ATLANTA, April 30, 2024 – The American Cancer Society’s new Addressing Barriers to Care grant program recently awarded a total of $500,000 to fund 15…
In this Article of the month podcast, Annals of Oncology Editor in Chief Tom Powles talks to Prof. Amanda Psyrri, of the National Kapodistrian University…